{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,7,7]],"date-time":"2026-07-07T03:42:22Z","timestamp":1783395742290,"version":"3.54.6"},"reference-count":55,"publisher":"MDPI AG","issue":"9","license":[{"start":{"date-parts":[[2025,9,1]],"date-time":"2025-09-01T00:00:00Z","timestamp":1756684800000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0\/"}],"funder":[{"name":"Knight Therapeutics"}],"content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":["JoF"],"abstract":"<jats:p>There are no data available on the effectiveness and safety of isavuconazole (ISA) for treating breakthrough invasive fungal infections (bIFIs). A retrospective and prospective cohort study was conducted between January 2020 and March 2025 in 13 centers in Argentina. Hematologic diseases (HD) and hematopoietic cell transplantation (HCT) patients who received ISA for IFI were included and followed for 12 weeks. Patients with proven and probable bIFIs and non-bIFIs were compared. One hundred and sixty-three patients were included. IFIs were classified as proven (13.5%), probable (26.9%) and possible (59.5%). Among 66 proven and probable IFIs, 53% were bIFIs, with aspergillosis and mucormycosis being the most common. Twenty-three (34.8%) patients had acute myelogenous leukemia, and 40.9% had received HCT. Forty-eight (72.7%) patients experienced neutropenia, with a median duration of 26 days (interquartile range [IQR] 16\u201344). Fluconazole and posaconazole were the most frequently received antifungal prophylaxis. ISA was prescribed as first-line therapy in 31 (46.9%) patients. The other 35 received ISA as a continuation therapy, mainly as a step-down therapy after liposomal amphotericin B. Four (6.1%) patients developed adverse effects, and one discontinued ISA. The 90-day overall clinical response between patients with bIFI vs. non-bIFI was 91.4% vs. 70.9% (p = 0.052). The 90-day overall and IFI-related mortality rates were, respectively, 11.4% vs. 32.3% (p = 0.068) and 5.7% vs. 9.7% (p = 0.659). The study data evidence ISA effectiveness and safety for the treatment of HD and HCT patients with and without bIFIs.<\/jats:p>","DOI":"10.3390\/jof11090648","type":"journal-article","created":{"date-parts":[[2025,9,2]],"date-time":"2025-09-02T13:01:13Z","timestamp":1756818073000},"page":"648","update-policy":"https:\/\/doi.org\/10.3390\/mdpi_crossmark_policy","source":"Crossref","is-referenced-by-count":1,"title":["Isavuconazole Therapy for Patients with Hematologic Diseases and Hematopoietic Cell Transplantation with and Without Breakthrough Invasive Fungal Infections"],"prefix":"10.3390","volume":"11","author":[{"given":"Fabi\u00e1n","family":"Herrera","sequence":"first","affiliation":[{"name":"Infectious Diseases Section, Internal Medicine Department, Centro de Educaci\u00f3n M\u00e9dica e Investigaciones Cl\u00ednicas (CEMIC), Buenos Aires C1431, Argentina"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0009-0001-3831-4561","authenticated-orcid":false,"given":"Diego","family":"Torres","sequence":"additional","affiliation":[{"name":"Infectious Diseases Section, Internal Medicine Department, Centro de Educaci\u00f3n M\u00e9dica e Investigaciones Cl\u00ednicas (CEMIC), Buenos Aires C1431, Argentina"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0003-0514-7004","authenticated-orcid":false,"given":"Gustavo","family":"Mendez","sequence":"additional","affiliation":[{"name":"Infectious Diseases Service, Hospital Dr. Ram\u00f3n Madariaga, Misiones N3300, Argentina"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0009-0008-2413-662X","authenticated-orcid":false,"given":"Noelia","family":"Ma\u00f1ez","sequence":"additional","affiliation":[{"name":"Infectious Diseases Section, Internal Medicine Department, Hospital Italiano de Buenos Aires, Buenos Aires C1199ABB, Argentina"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Rosana","family":"Jord\u00e1n","sequence":"additional","affiliation":[{"name":"Infectious Diseases Service, Hospital Brit\u00e1nico de Buenos Aires, Buenos Aires C1280AEB, Argentina"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Adriana","family":"Manzur","sequence":"additional","affiliation":[{"name":"Infectious Diseases Service, Hospital Rawson, San Juan J5400, Argentina"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0009-0002-7158-2258","authenticated-orcid":false,"given":"Myrna","family":"Cabral","sequence":"additional","affiliation":[{"name":"Infectious Diseases Service, Hospital Central, Mendoza M5502, Argentina"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Manuel","family":"Alderete","sequence":"additional","affiliation":[{"name":"Instituto Alexander Fleming, Buenos Aires C1426, Argentina"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Natalia","family":"Garc\u00eda Allende","sequence":"additional","affiliation":[{"name":"Infectious Diseases Service, Hospital Alem\u00e1n, Buenos Aires C1118AAT, Argentina"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jos\u00e9","family":"Benso","sequence":"additional","affiliation":[{"name":"Infectious Diseases Section, Internal Medicine Department, Hospital Italiano de San Justo, Buenos Aires B1754AZK, Argentina"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0009-0003-4158-6255","authenticated-orcid":false,"given":"Claudia","family":"Salgueira","sequence":"additional","affiliation":[{"name":"Infectious Diseases Service, Sanatorio Anchorena, Buenos Aires C1425, Argentina"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Mar\u00eda Laura","family":"Pereyra","sequence":"additional","affiliation":[{"name":"Infectious Diseases Service, Hospital Universitario Austral, Buenos Aires B1629, Argentina"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Hugo","family":"Peretti","sequence":"additional","affiliation":[{"name":"Hematopoietic Stem Cell Transplant Unit, Sanatorio Brit\u00e1nico, Rosario S2000, Argentina"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Carla","family":"Niveyro","sequence":"additional","affiliation":[{"name":"Infectious Diseases Service, Hospital Dr. Ram\u00f3n Madariaga, Misiones N3300, Argentina"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0003-0112-8455","authenticated-orcid":false,"given":"Maximiliano","family":"Castro","sequence":"additional","affiliation":[{"name":"Infectious Diseases Section, Internal Medicine Department, Centro de Educaci\u00f3n M\u00e9dica e Investigaciones Cl\u00ednicas (CEMIC), Buenos Aires C1431, Argentina"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Federico","family":"Pollastrelli","sequence":"additional","affiliation":[{"name":"Infectious Diseases Service, Hospital Brit\u00e1nico de Buenos Aires, Buenos Aires C1280AEB, Argentina"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Silvina","family":"Garc\u00eda Rojas","sequence":"additional","affiliation":[{"name":"Infectious Diseases Service, Hospital Brit\u00e1nico de Buenos Aires, Buenos Aires C1280AEB, Argentina"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Juan","family":"Dap\u00e1s","sequence":"additional","affiliation":[{"name":"Infectious Diseases Service, Hospital Central, Mendoza M5502, Argentina"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Agustina","family":"Risso Patr\u00f3n","sequence":"additional","affiliation":[{"name":"Infectious Diseases Service, Hospital Alem\u00e1n, Buenos Aires C1118AAT, Argentina"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0009-0004-7059-0138","authenticated-orcid":false,"given":"Ver\u00f3nica","family":"Fern\u00e1ndez","sequence":"additional","affiliation":[{"name":"Infectious Diseases Section, Internal Medicine Department, Hospital Italiano de San Justo, Buenos Aires B1754AZK, Argentina"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Roc\u00edo","family":"Gago","sequence":"additional","affiliation":[{"name":"Infectious Diseases Service, Hospital Universitario Austral, Buenos Aires B1629, Argentina"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Javier","family":"Afeltra","sequence":"additional","affiliation":[{"name":"Microbiology Laboratory, Hospital Dr. Jos\u00e9 Mar\u00eda Ramos Mej\u00eda, Buenos Aires C1221ADC, Argentina"}],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"1968","published-online":{"date-parts":[[2025,9,1]]},"reference":[{"key":"ref_1","doi-asserted-by":"crossref","unstructured":"Wasylyshyn, A.I., Linder, K.A., Kauffman, C.A., Richards, B.J., Maurer, S.M., Sheffield, V.M., Benitez Colon, L., and Miceli, M.H. (2021). Invasive Fungal Disease in Patients with Newly Diagnosed Acute Myeloid Leukemia. J. Fungi, 7.","DOI":"10.3390\/jof7090761"},{"key":"ref_2","doi-asserted-by":"crossref","first-page":"39959","DOI":"10.1097\/MD.0000000000039959","article-title":"Invasive fungal infections in patients with acute leukemia: A retrospective cohort study at a tertiary-care hospital","volume":"103","author":"Alkan","year":"2024","journal-title":"Medicine"},{"key":"ref_3","doi-asserted-by":"crossref","first-page":"872","DOI":"10.1016\/j.bbmt.2014.03.004","article-title":"Incidence and outcome of invasive fungal diseases after allogeneic stem cell transplantation: A prospective study of the Gruppo Italiano Trapianto Midollo Osseo (GITMO)","volume":"20","author":"Girmenia","year":"2014","journal-title":"Biol. Blood Marrow Transplant."},{"key":"ref_4","doi-asserted-by":"crossref","first-page":"15","DOI":"10.1016\/j.ajic.2010.06.009","article-title":"The economic costs to United States hospitals of invasive fungal infections in transplant patients","volume":"39","author":"Menzin","year":"2011","journal-title":"Am. J. Infect. Control"},{"key":"ref_5","doi-asserted-by":"crossref","first-page":"1304","DOI":"10.1038\/s41409-018-0161-1","article-title":"Hematopoietic cell transplantation comorbidity index and risk of developing invasive fungal infections after allografting","volume":"53","author":"Busca","year":"2018","journal-title":"Bone Marrow Transplant."},{"key":"ref_6","doi-asserted-by":"crossref","first-page":"1091","DOI":"10.1086\/651263","article-title":"Prospective surveillance for invasive fungal infections in hematopoietic stem cell transplant recipients, 2001-2006: Overview of the Transplant-Associated Infection Surveillance Network (TRANSNET) Database","volume":"50","author":"Kontoyiannis","year":"2010","journal-title":"Clin. Infect. Dis."},{"key":"ref_7","doi-asserted-by":"crossref","first-page":"265","DOI":"10.1086\/595846","article-title":"Epidemiology and outcome of invasive fungal infection in adult hematopoietic stem cell transplant recipients: Analysis of Multicenter Prospective Antifungal Therapy (PATH) Alliance registry","volume":"48","author":"Neofytos","year":"2009","journal-title":"Clin. Infect. Dis."},{"key":"ref_8","doi-asserted-by":"crossref","first-page":"ofab596","DOI":"10.1093\/ofid\/ofab596","article-title":"Invasive Mold Infections in Allogeneic Hematopoietic Cell Transplant Recipients in 2020: Have We Made Enough Progress?","volume":"9","author":"Roth","year":"2021","journal-title":"Open Forum Infect. Dis."},{"key":"ref_9","doi-asserted-by":"crossref","first-page":"5471","DOI":"10.1200\/JCO.2007.12.3851","article-title":"Antifungal prophylaxis in cancer patients after chemotherapy or hematopoietic stem-cell transplantation: Systematic review and meta-analysis","volume":"25","author":"Robenshtok","year":"2007","journal-title":"J. Clin. Oncol."},{"key":"ref_10","doi-asserted-by":"crossref","unstructured":"Zeng, H., Wu, Z., Yu, B., Wang, B., Wu, C., Wu, J., Lai, J., Gao, X., and Chen, J. (2021). Network meta-analysis of triazole, polyene, and echinocandin antifungal agents in invasive fungal infection prophylaxis in patients with hematological malignancies. BMC Cancer, 21.","DOI":"10.1186\/s12885-021-07973-8"},{"key":"ref_11","doi-asserted-by":"crossref","first-page":"ofae082","DOI":"10.1093\/ofid\/ofae082","article-title":"Modeling Invasive Aspergillosis Risk for the Application of Prophylaxis Strategies","volume":"11","author":"Young","year":"2024","journal-title":"Open Forum Infect. Dis."},{"key":"ref_12","doi-asserted-by":"crossref","first-page":"1","DOI":"10.1016\/j.cmi.2018.01.002","article-title":"Diagnosis and management of Aspergillus diseases: Executive summary of the 2017 ESCMID-ECMM-ERS guideline","volume":"24","author":"Ullmann","year":"2018","journal-title":"Clin. Microbiol. Infect."},{"key":"ref_13","doi-asserted-by":"crossref","first-page":"201","DOI":"10.1016\/j.jtct.2020.10.003","article-title":"American Society of Transplantation and Cellular Therapy Series, 2: Management and Prevention of Aspergillosis in Hematopoietic Cell Transplantation Recipients","volume":"27","author":"Dadwal","year":"2021","journal-title":"Transplant. Cell. Ther."},{"key":"ref_14","doi-asserted-by":"crossref","first-page":"1813","DOI":"10.1093\/jac\/dkad143","article-title":"Primary prophylaxis of invasive fungal diseases in patients with haematological malignancies: 2022 update of the recommendations of the Infectious Diseases Working Party (AGIHO) of the German Society for Haematology and Medical Oncology (DGHO)","volume":"78","author":"Stemler","year":"2023","journal-title":"J. Antimicrob. Chemother."},{"key":"ref_15","doi-asserted-by":"crossref","first-page":"e1","DOI":"10.1093\/cid\/ciw326","article-title":"Practice Guidelines for the Diagnosis and Management of Aspergillosis: 2016 Update by the Infectious Diseases Society of America","volume":"63","author":"Patterson","year":"2016","journal-title":"Clin. Infect. Dis."},{"key":"ref_16","doi-asserted-by":"crossref","first-page":"1547","DOI":"10.1038\/s41375-025-02586-7","article-title":"Primary antifungal prophylaxis in hematological malignancies. Updated clinical practice guidelines by the European Conference on Infections in Leukemia (ECIL)","volume":"39","author":"Pagano","year":"2025","journal-title":"Leukemia"},{"key":"ref_17","doi-asserted-by":"crossref","first-page":"151","DOI":"10.1093\/cid\/ciae203","article-title":"Breakthrough Invasive Fungal Infections in Patients With High-Risk Hematological Disorders Receiving Voriconazole and Posaconazole Prophylaxis: A Systematic Review","volume":"79","author":"Boutin","year":"2024","journal-title":"Clin. Infect. Dis."},{"key":"ref_18","doi-asserted-by":"crossref","first-page":"ofaf163","DOI":"10.1093\/ofid\/ofaf163","article-title":"Incidence of Breakthrough Fungal Infections in Patients With Isavuconazole Prophylaxis: A Systematic Review and Meta-analysis","volume":"12","author":"Ishida","year":"2025","journal-title":"Open Forum Infect. Dis."},{"key":"ref_19","doi-asserted-by":"crossref","first-page":"1621","DOI":"10.1093\/cid\/ciy473","article-title":"Breakthrough Invasive Mold Infections in the Hematology Patient: Current Concepts and Future Directions","volume":"67","author":"Lionakis","year":"2018","journal-title":"Clin. Infect. Dis."},{"key":"ref_20","doi-asserted-by":"crossref","first-page":"S127","DOI":"10.1093\/mmy\/myy091","article-title":"Breakthrough invasive fungal diseases in acute myeloid leukemia patients receiving mould active triazole primary prophylaxis after intensive chemotherapy: An Italian consensus agreement on definitions and management","volume":"57","author":"Girmenia","year":"2019","journal-title":"Med. Mycol."},{"key":"ref_21","doi-asserted-by":"crossref","first-page":"760","DOI":"10.1016\/S0140-6736(15)01159-9","article-title":"Isavuconazole versus voriconazole for primary treatment of invasive mould disease caused by Aspergillus and other filamentous fungi (SECURE): A phase 3, randomised-controlled, non-inferiority trial","volume":"387","author":"Maertens","year":"2016","journal-title":"Lancet"},{"key":"ref_22","doi-asserted-by":"crossref","first-page":"828","DOI":"10.1016\/S1473-3099(16)00071-2","article-title":"Isavuconazole treatment for mucormycosis: A single-arm open-label trial and case-control analysis","volume":"16","author":"Marty","year":"2016","journal-title":"Lancet Infect. Dis."},{"key":"ref_23","unstructured":"EMA (2015). Cresemba (Isavuconazole). EPAR Summary for the Public, European Medicines Agency. Available online: https:\/\/www.ema.europa.eu\/en\/medicines\/human\/EPAR\/cresemba."},{"key":"ref_24","unstructured":"FDA (2025, August 22). FDA Approves Cresemba (Isavuconazonium sulfate) for Invasive Aspergillosis and Invasive Mucormycosis, Available online: https:\/\/www.accessdata.fda.gov\/scripts\/cder\/daf\/index.cfm?event=overview.process&ApplNo=207500."},{"key":"ref_25","doi-asserted-by":"crossref","first-page":"405","DOI":"10.1016\/S1473-3099(19)30312-3","article-title":"Global guideline for the diagnosis and management of mucormycosis: An initiative of the European Confederation of Medical Mycology in cooperation with the Mycoses Study Group Education and Research Consortium","volume":"19","author":"Cornely","year":"2019","journal-title":"Lancet Infect. Dis."},{"key":"ref_26","doi-asserted-by":"crossref","first-page":"534","DOI":"10.1111\/myc.12910","article-title":"Real-world use-Isavuconazole at a large academic medical center","volume":"62","author":"Hassouna","year":"2019","journal-title":"Mycoses"},{"key":"ref_27","doi-asserted-by":"crossref","unstructured":"Gow-Lee, V., Abu Saleh, O.M., Harris, C.E., Gile, J.J., Akhiyat, N., and Chesdachai, S. (2024). Outcomes of Invasive Fungal Infections Treated with Isavuconazole: A Retrospective Review. Pathogens, 13.","DOI":"10.3390\/pathogens13100886"},{"key":"ref_28","doi-asserted-by":"crossref","unstructured":"Gunathilaka, S.S., Keragala, R.K., Gunathilaka, K.M., Wickramage, S., Bandara, S.R., Senevirathne, I.S., and Jayaweera, A.S. (2025). Use of isavuconazole in mucormycosis: A systematic review. BMC Infect. Dis., 25.","DOI":"10.1186\/s12879-025-10439-y"},{"key":"ref_29","doi-asserted-by":"crossref","unstructured":"Dagher, H., Hachem, R., Chaftari, A.M., Jiang, Y., Ali, S., Deeba, R., Shah, S., and Raad, I. (2022). Real-World Use of Isavuconazole as Primary Therapy for Invasive Fungal Infections in High-Risk Patients with Hematologic Malignancy or Stem Cell Transplant. J. Fungi, 8.","DOI":"10.3390\/jof8010074"},{"key":"ref_30","doi-asserted-by":"crossref","unstructured":"Weng, J., Du, X., Fang, B., Li, Y., Huang, L., and Ju, Y. (2025). Efficacy and safety of isavuconazole versus voriconazole for the treatment of invasive fungal infections: A meta-analysis with trial sequential analysis. BMC Infect. Dis., 25.","DOI":"10.1186\/s12879-025-10627-w"},{"key":"ref_31","doi-asserted-by":"crossref","unstructured":"Ellsworth, M., and Ostrosky-Zeichner, L. (2020). Isavuconazole: Mechanism of Action, Clinical Efficacy, and Resistance. J. Fungi, 6.","DOI":"10.3390\/jof6040324"},{"key":"ref_32","doi-asserted-by":"crossref","first-page":"0017722","DOI":"10.1128\/aac.00177-22","article-title":"New Perspectives on Antimicrobial Agents: Isavuconazole","volume":"66","author":"Lewis","year":"2022","journal-title":"Antimicrob. Agents Chemother."},{"key":"ref_33","doi-asserted-by":"crossref","first-page":"10","DOI":"10.1128\/AAC.00585-18","article-title":"Isavuconazole Concentration in Real-World Practice: Consistency with Results from Clinical Trials","volume":"62","author":"Andes","year":"2018","journal-title":"Antimicrob. Agents Chemother."},{"key":"ref_34","doi-asserted-by":"crossref","unstructured":"Risum, M., Vestergaard, M.B., Weinreich, U.M., Helleberg, M., Vissing, N.H., and J\u00f8rgensen, R. (2021). Therapeutic Drug Monitoring of Isavuconazole: Serum Concentration Variability and Success Rates for Reaching Target in Comparison with Voriconazole. Antibiotics, 10.","DOI":"10.3390\/antibiotics10050487"},{"key":"ref_35","doi-asserted-by":"crossref","first-page":"1203","DOI":"10.1093\/jac\/dkae103","article-title":"Triazole antifungal drug interactions-practical considerations for excellent prescribing","volume":"79","author":"Lewis","year":"2024","journal-title":"J. Antimicrob. Chemother."},{"key":"ref_36","doi-asserted-by":"crossref","first-page":"81","DOI":"10.1111\/myc.12851","article-title":"Tolerability of isavuconazole after posaconazole toxicity in leukaemia patients","volume":"62","author":"DiPippo","year":"2019","journal-title":"Mycoses"},{"key":"ref_37","doi-asserted-by":"crossref","first-page":"1367","DOI":"10.1093\/cid\/ciz1008","article-title":"Revision and Update of the Consensus Definitions of Invasive Fungal Disease From the European Organization for Research and Treatment of Cancer and the Mycoses Study Group Education and Research Consortium","volume":"71","author":"Donnelly","year":"2020","journal-title":"Clin. Infect. Dis."},{"key":"ref_38","doi-asserted-by":"crossref","first-page":"716","DOI":"10.1111\/myc.12960","article-title":"Defining breakthrough invasive fungal infection-Position paper of the mycoses study group education and research consortium and the European Confederation of Medical Mycology","volume":"62","author":"Cornely","year":"2019","journal-title":"Mycoses"},{"key":"ref_39","first-page":"825","article-title":"1994 Consensus Conference on Acute GVHD Grading","volume":"15","author":"Przepiorka","year":"1995","journal-title":"Bone Marrow Transplant."},{"key":"ref_40","doi-asserted-by":"crossref","first-page":"17","DOI":"10.1016\/j.blre.2016.09.002","article-title":"Risk stratification for invasive fungal infections in patients with hematological malignancies: SEIFEM recommendations","volume":"31","author":"Pagano","year":"2017","journal-title":"Blood Rev."},{"key":"ref_41","doi-asserted-by":"crossref","unstructured":"Batista, M.V., Ussetti, M.P., Jiang, Y., Neofytos, D., Cortez, A.C., Feriani, D., Schmidt-Filho, J., Fran\u00e7a-Silva, I.L.A., Raad, I., and Hachem, R. (2023). Comparing the Real-World Use of Isavuconazole to Other Anti-Fungal Therapy for Invasive Fungal Infections in Patients with and without Underlying Disparities: A Multi-Center Retrospective Study. J. Fungi, 9.","DOI":"10.3390\/jof9020166"},{"key":"ref_42","doi-asserted-by":"crossref","first-page":"46","DOI":"10.1016\/j.jinf.2023.05.005","article-title":"Breakthrough invasive fungal infection among patients with haematologic malignancies: A national, prospective, and multicentre study","volume":"87","author":"Ramos","year":"2023","journal-title":"J. Infect."},{"key":"ref_43","doi-asserted-by":"crossref","first-page":"401","DOI":"10.1016\/j.ijantimicag.2015.05.017","article-title":"Influence of mould-active antifungal treatment on the performance of the Aspergillus-specific bronchoalveolar lavage fluid lateral-flow device test","volume":"46","author":"Eigl","year":"2015","journal-title":"Int. J. Antimicrob. Agents"},{"key":"ref_44","first-page":"528","article-title":"Galactomannan testing and Aspergillus PCR in same-day bronchoalveolar lavage and blood samples for diagnosis of invasive aspergillosis","volume":"55","author":"Eigl","year":"2017","journal-title":"Med. Mycol."},{"key":"ref_45","doi-asserted-by":"crossref","unstructured":"Jenks, J.D., Gangneux, J.P., Schwartz, I.S., Alastruey-Izquierdo, A., Lagrou, K., Thompson Iii, G.R., Lass-Fl\u00f6rl, C., and Hoenigl, M. (2020). European Confederation of Medical Mycology (ECMM) Council Investigators. Diagnosis of Breakthrough Fungal Infections in the Clinical Mycology Laboratory: An ECMM Consensus Statement. J. Fungi, 6.","DOI":"10.20944\/preprints202008.0672.v1"},{"key":"ref_46","doi-asserted-by":"crossref","first-page":"653","DOI":"10.1111\/myc.13082","article-title":"Treatment of invasive fungal diseases in cancer patients-Revised 2019 Recommendations of the Infectious Diseases Working Party (AGIHO) of the German Society of Hematology and Oncology (DGHO)","volume":"63","author":"Ruhnke","year":"2020","journal-title":"Mycoses"},{"key":"ref_47","doi-asserted-by":"crossref","first-page":"499","DOI":"10.1016\/S0140-6736(21)00219-1","article-title":"study investigators. Posaconazole versus voriconazole for primary treatment of invasive aspergillosis: A phase 3, randomised, controlled, non-inferiority trial","volume":"397","author":"Maertens","year":"2021","journal-title":"Lancet"},{"key":"ref_48","doi-asserted-by":"crossref","first-page":"362","DOI":"10.1093\/cid\/civ885","article-title":"Azole Resistance in Aspergillus fumigatus: Can We Retain the Clinical Use of Mold-Active Antifungal Azoles?","volume":"62","author":"Verweij","year":"2016","journal-title":"Clin. Infect. Dis."},{"key":"ref_49","doi-asserted-by":"crossref","first-page":"2902","DOI":"10.1093\/jac\/dkx228","article-title":"Risk factors for subtherapeutic levels of posaconazole tablet","volume":"72","author":"Tang","year":"2017","journal-title":"J. Antimicrob. Chemother."},{"key":"ref_50","doi-asserted-by":"crossref","first-page":"e00101-17","DOI":"10.1128\/AAC.00101-17","article-title":"Impact of Mucositis on Absorption and Systemic Drug Exposure of Isavuconazole","volume":"61","author":"Kovanda","year":"2017","journal-title":"Antimicrob. Agents Chemother."},{"key":"ref_51","doi-asserted-by":"crossref","first-page":"1195","DOI":"10.1016\/j.bbmt.2020.02.009","article-title":"A Single-Center, Open-Label Trial of Isavuconazole Prophylaxis against Invasive Fungal Infection in Patients Undergoing Allogeneic Hematopoietic Cell Transplantation","volume":"26","author":"Stern","year":"2020","journal-title":"Biol. Blood Marrow Transplant."},{"key":"ref_52","doi-asserted-by":"crossref","first-page":"373","DOI":"10.1086\/509917","article-title":"Imaging findings in acute invasive pulmonary aspergillosis: Clinical significance of the halo sign","volume":"44","author":"Greene","year":"2007","journal-title":"Clin. Infect. Dis."},{"key":"ref_53","doi-asserted-by":"crossref","first-page":"405","DOI":"10.1093\/cid\/ciu833","article-title":"Serum galactomannan versus a combination of galactomannan and polymerase chain reaction-based Aspergillus DNA detection for early therapy of invasive aspergillosis in high-risk hematological patients: A randomized controlled trial","volume":"60","author":"Aguado","year":"2015","journal-title":"Clin. Infect. Dis."},{"key":"ref_54","doi-asserted-by":"crossref","first-page":"240","DOI":"10.1111\/myc.12149","article-title":"Prospective antifungal therapy (PATH) alliance(\u00ae): Focus on mucormycosis","volume":"57","author":"Kontoyiannis","year":"2014","journal-title":"Mycoses"},{"key":"ref_55","doi-asserted-by":"crossref","first-page":"e01034-17","DOI":"10.1128\/AAC.01034-17","article-title":"Exposure-Response Relationships for Isavuconazole in Patients with Invasive Aspergillosis and Other Filamentous Fungi","volume":"61","author":"Desai","year":"2017","journal-title":"Antimicrob. Agents Chemother."}],"container-title":["Journal of Fungi"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/www.mdpi.com\/2309-608X\/11\/9\/648\/pdf","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2025,10,9]],"date-time":"2025-10-09T18:37:28Z","timestamp":1760035048000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.mdpi.com\/2309-608X\/11\/9\/648"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2025,9,1]]},"references-count":55,"journal-issue":{"issue":"9","published-online":{"date-parts":[[2025,9]]}},"alternative-id":["jof11090648"],"URL":"https:\/\/doi.org\/10.3390\/jof11090648","relation":{},"ISSN":["2309-608X"],"issn-type":[{"value":"2309-608X","type":"electronic"}],"subject":[],"published":{"date-parts":[[2025,9,1]]}}}